The completion of this study could positively impact AstraZeneca’s stock performance by enhancing investor confidence in their oncology pipeline. As the company continues to innovate in cancer ...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, ...

The leading ER+/ HER2 -ve Breast Cancer Companies such as AstraZeneca, Atossa Therapeutics, Inc., Accutar Biotechnology Inc, ...

Antibody-drug conjugates are currently being investigated in more than 260 clinical trials.“It’s going to be the next novel ...

AstraZeneca (AZ) has announced that Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) has been recommended by ...

In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...

Despite challenges in the biopharma sector, Sophia Genetics SA (SOPH) showcases robust growth and strategic advancements in ...

From new payload linkers to artificial intelligence partnerships, advances in ADC pipelines push forward selective cancer therapies that minimize side effects.

Q2 2025 Earnings Call Transcript August 5, 2025 Personalis, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.25. Operator: Ladies and gentlemen, greetings, and welcome ...

SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and leader in data-driven medicine, today reported financial results for the second quarter ended June 30, 2025.

Portfolio Receipts was $727 million in the second quarter of 2025, an increase of 20% compared to $608 million in the second quarter of 2024, primarily driven by the same Royalty Receipts increases ...